Contact Supplier

Contact Supplier

To get in touch with Bachem AG, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier

    Bachem webinar on selecting the right peptide & oligonucleotide CDMO

    news-releasesBachem AG
    February 4th 2022

    Bubendorf, Switzerland: –Peptide technology specialist Bachem’s latest online webinar later this month will focus on finding the right development strategy and contract development and manufacturing partners for peptide and oligonucleotide based drugs.

    The webinar ‘Trends in peptides and oligonucleotides – choosing a partner CDMO’ will look at the foreseeable future of peptides and oligonucleotides as versatile therapeutics with a growing range of applications and many similarities in terms of manufacturing and regulation.

    Complex questions

    Since innovative formulations often increase the complexity of the products and demand similarly innovative solutions, it becomes crucial for pharma drug developers to partner with a suitably experienced CDMO to support their product development and manufacturing needs and allow them to focus on their core role as researchers and innovators.

    The webinar is free to register (see Resources) and will be hosted online on February 24, 2022, from 1730 hrs CEST (UTC+1).

    Webinar hosts

    The session will be moderated by Head of Bachem Group Communication, Dr. Daniel Grotzky, with key insights from Bachem Group Leader for Product Management, Dr. Tycho Leifels.

    Dr. Leifels is an experienced life science portfolio professional with a 17 year track record of leading business development and pipeline strategy in various commercial roles in the life science industry including successful international product launches.

    Dr. Grotzky is responsible for Bachem’s internal and external communications and investor relations, with a strong track record of communications in the life science industry, including more than a decade of experience in various communication leadership roles at the biopharmaceutical and diagnostics company Roche.

    About Bachem

    Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With over 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

    Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.

    Resources

    Click on Bachem webinar on selecting the right peptide & oligonucleotide CDMO to register for the event.
    Subscribe to Bachems Newsletter to receive the latest updates.

    Bachem webinar on selecting the right peptide & oligonucleotide CDMO
    Bachem webinar on selecting the right peptide & oligonucleotide CDMO

    Dr. Daniel Grotzky, Head of Group Communication, Bachem Holding

    Bachem webinar on selecting the right peptide & oligonucleotide CDMO

    Dr. Tycho Leifels, Group Leader Product Management, Bachem AG

    Contact Bachem AG

    Simply fill out the form below to contact Bachem AG now.

    Send Bachem AG a Message